Indeed, PR3 was found to cleave IL-32γ, leading to elevated expression of proinflammatory cytokines in KCs; however, pretreatment with a PR3 inhibitor effectively reversed these effects, validating our hypothesis (Fig. 8f, g). Here, PRTN3 is linked to dry eye syndrome.